EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Wnt inhibition alleviates resistance to anti-PD1 therapy and improves antitumor immunity in glioblastoma

Shanmugarajan Krishnan iD, Somin Lee, Zohreh Amoozgar iD, Sonu Subudhi iD, Ashwin Srinivasan Kumar iD, Jessica M Posada, Neal Lindeman, Pinji Lei, Mark Duquette, Sophie Steinbuch, Marc Charabati, Peigen Huang und 5 weitere

Proceedings of the National Academy of Sciences · 23.09.2025 · 122 (38)

DOI: 10.1073/pnas.2414941122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 15.09.2025. Verfasst von Shanmugarajan Krishnan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114. Hauptthemen laut MEDLINE: Glioblastoma, Wnt Proteins, Brain Neoplasms, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Wnt signaling plays a crucial role for many developmental processes. It is also pivotal in the generation and limited treatment outcomes of glioblastoma (GBM). Here, we identified Wnt7b, which is markedly upregulated in GBM patients, as a determinant of resistance to immune checkpoint blockers (αPD1; anti-Programmed Cell Death Protein 1) in a clinically relevant, αPD1-resistant GBM murine model with abundant stem cells. We observed that increased levels of Wnt7b and β-catenin correlated with the resistance to αPD1. Treatment combining a porcupine inhibitor WNT974 with αPD1 reprogrammed the immune suppressive tumor microenvironment (TME) to bolster antitumor immune responses and extended the survival of mice bearing orthotopic GBM, with 25% long-term survivors. Our causal studies revealed that WNT974 potentiated αPD1 therapy by the expansion of antigen presenting DC3-like dendritic cells (DCs). Additionally, WNT974 combination with αPD1 was associated with a reduction in immune suppressive granulocytic myeloid-derived suppressor cells (MDSCs), an increase in the Ki67+CD8/Ki67+regulatory T cells (Treg) ratio, tilting the CD8:Treg balance in the TME toward antitumor immune response, and more pronounced GrzB+CD8+ effector T cells. Conversely, an increase in monocytic MDSCs and phosphorylation of pro-oncogenic proteins was associated with resistance to the combination therapy. Collectively, our preclinical findings provide a strong rationale to test Wnt7b/β-catenin inhibition with αPD1 therapy in GBM patients with elevated Wnt7b/β-catenin signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaWnt ProteinsBrain NeoplasmsProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsImmunotherapyAntineoplastic Agents, ImmunologicalWnt Signaling PathwayCell Line, TumorHumansFemaleAnimalsMiceDrug Resistance, NeoplasmTumor Microenvironmentbeta CateninPyridinesBenzeneacetamidesMice, Inbred C57BLMale

Stichwörter der Autor:innen

Wnt7b/β-catenindendritic cellsglioblastomaimmunotherapystem cells

Substanzen

Wnt ProteinsProgrammed Cell Death 1 ReceptorImmune Checkpoint Inhibitorsbeta Catenin2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl)acetamidePyridinesBenzeneacetamidesAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115.
  • Department of Dermatology, University Medical Center Bonn, Bonn 53127, Germany.

ORCID-Profile: Shanmugarajan Krishnan, Zohreh Amoozgar, Sonu Subudhi, Ashwin Srinivasan Kumar, Meenal Datta, Lance L Munn, Dai Fukumura, Rakesh K Jain

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS
  • NIBIB NIH HHS
  • DOD | U.S. Army (USA)
  • NIMH NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Krishnan, S., Lee, S., Amoozgar, Z., Subudhi, S., Srinivasan Kumar, A., Posada, J. M., Lindeman, N., Lei, P., Duquette, M., Steinbuch, S., Charabati, M., Huang, P., Andersson, P., Datta, M., Munn, L. L., Fukumura, D., & Jain, R. K. (2025). Wnt inhibition alleviates resistance to anti-PD1 therapy and improves antitumor immunity in glioblastoma. Proceedings of the National Academy of Sciences, 122(38). https://doi.org/10.1073/pnas.2414941122

Vancouver

Krishnan S, Lee S, Amoozgar Z, Subudhi S, Srinivasan Kumar A, Posada JM, et al. Wnt inhibition alleviates resistance to anti-PD1 therapy and improves antitumor immunity in glioblastoma. Proceedings of the National Academy of Sciences. 2025;122(38). doi:10.1073/pnas.2414941122

BibTeX
@article{Krishnan2025,
  author = {Krishnan, Shanmugarajan and Lee, Somin and Amoozgar, Zohreh and Subudhi, Sonu and Srinivasan Kumar, Ashwin and Posada, Jessica M and Lindeman, Neal and Lei, Pinji and Duquette, Mark and Steinbuch, Sophie and Charabati, Marc and Huang, Peigen and Andersson, Patrik and Datta, Meenal and Munn, Lance L and Fukumura, Dai and Jain, Rakesh K},
  title = {Wnt inhibition alleviates resistance to anti-PD1 therapy and improves antitumor immunity in glioblastoma},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {38},
  doi = {10.1073/pnas.2414941122}
}
Kostenlos starten →